[go: up one dir, main page]

MX2024012473A - Formulaciones farmaceuticas de liberacion modificada que comprenden deferiprona - Google Patents

Formulaciones farmaceuticas de liberacion modificada que comprenden deferiprona

Info

Publication number
MX2024012473A
MX2024012473A MX2024012473A MX2024012473A MX2024012473A MX 2024012473 A MX2024012473 A MX 2024012473A MX 2024012473 A MX2024012473 A MX 2024012473A MX 2024012473 A MX2024012473 A MX 2024012473A MX 2024012473 A MX2024012473 A MX 2024012473A
Authority
MX
Mexico
Prior art keywords
deferiprone
pharmaceutical formulations
modified release
release pharmaceutical
directed
Prior art date
Application number
MX2024012473A
Other languages
English (en)
Inventor
Marisa Pertile
Andrea Gazzaniga
Matteo Cerea
Micol Cirilli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/717,913 external-priority patent/US12016850B2/en
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2024012473A publication Critical patent/MX2024012473A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se dirige a composiciones farmacéuticas para administración oral que comprenden deferiprona. En particular, la invención también se dirige a comprimidos de liberación retardada adecuados para administración dos veces al día o una vez al día. La invención también se dirige a métodos de fabricación y uso de los mismos.
MX2024012473A 2022-04-11 2024-10-08 Formulaciones farmaceuticas de liberacion modificada que comprenden deferiprona MX2024012473A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/717,913 US12016850B2 (en) 2022-04-11 2022-04-11 Modified release pharmaceutical formulations comprising deferiprone
EP22167557 2022-04-11
PCT/EP2023/059304 WO2023198641A1 (en) 2022-04-11 2023-04-07 Modified release pharmaceutical formulations comprising deferiprone

Publications (1)

Publication Number Publication Date
MX2024012473A true MX2024012473A (es) 2024-11-08

Family

ID=86099807

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012473A MX2024012473A (es) 2022-04-11 2024-10-08 Formulaciones farmaceuticas de liberacion modificada que comprenden deferiprona

Country Status (8)

Country Link
EP (1) EP4507678A1 (es)
JP (1) JP2025512012A (es)
KR (1) KR20250002399A (es)
CN (1) CN119300809A (es)
AU (1) AU2023254403A1 (es)
CA (1) CA3248497A1 (es)
MX (1) MX2024012473A (es)
WO (1) WO2023198641A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
AU2003280818A1 (en) 2002-11-18 2004-06-15 Nippon Unicar Company Limited Odorless polyether-modified polysiloxane composition, process for the production thereof, and cosmetics containing the same
CA3172668A1 (en) 2017-10-25 2019-05-02 Chiesi Farmaceutici S.P.A. Delayed release deferiprone tablets and methods of using the same

Also Published As

Publication number Publication date
CN119300809A (zh) 2025-01-10
KR20250002399A (ko) 2025-01-07
CA3248497A1 (en) 2023-10-19
EP4507678A1 (en) 2025-02-19
JP2025512012A (ja) 2025-04-16
WO2023198641A1 (en) 2023-10-19
AU2023254403A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
EP4282414A3 (en) Modified release tablet formulations containing phosphodiesterase inhibitors
PH12020550341A1 (en) Niraparib formulations
JOP20220179A1 (ar) N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
MX2009001711A (es) Formulaciones de liberacion sostenida de topiramato.
ZA202300259B (en) Compound for the treatment of coronaviral infections
WO2023205463A8 (en) Heteroaryl compounds for the treatment of pain
MY145790A (en) Composition
MX2009007784A (es) Composiciones de tiacumicinas estables.
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
EA201290734A1 (ru) Рифаксимин в форме порошка, способ его получения и композиции контролируемого высвобождения, содержащие указанный рифаксимин, полезные для достижения длительного эффекта
CR20240514A (es) Compuestos de heteroarilo para el tratamiento del dolor
EP4364802A3 (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same
EP4223785A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY-DRUG CONJUGATE, AND USE OF THE PHARMACEUTICAL COMPOSITION
MX2023005971A (es) Metodos y composicion para las modificaciones de kras.
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
MXPA05008843A (es) Sistema terapeutico que comprende amoxicilina y acido clavulanico.
MX2024012473A (es) Formulaciones farmaceuticas de liberacion modificada que comprenden deferiprona
WO2020190900A8 (en) Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
WO2023096615A3 (en) A compressed solid oral dosage form comprising pinaverium and medazepam
MX2023000479A (es) Composiciones farmaceuticas orales hinchables.
MD2516C2 (ro) Remediu medicamentos antiinflamator, antiseptic şi antifungic sub formă de gel
MX2021004553A (es) Composiciones farmaceuticas y metodos para fabricar formulaciones de dosificacion solidas bajo demanda.
WO2024231881A3 (en) Polymorphic forms and formulations of leriglitazone
MX2025000908A (es) Composiciones farmaceuticas de nor-udca